Editorial: Rising Stars in Hematologic Malignancies 2021.
作者信息
Qian Liren, De Lima Marcos, Mims Alice S, Epperla Narendranath
机构信息
Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Department of Medicine, Division of Hematology, The Ohio State University, Columbus, OH, United States.
出版信息
Front Oncol. 2022 Feb 25;12:858564. doi: 10.3389/fonc.2022.858564. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Rising Stars in Hematologic Malignancies 2021.社论：2021年血液系统恶性肿瘤领域的后起之秀
Front Oncol. 2022 Feb 25;12:858564. doi: 10.3389/fonc.2022.858564. eCollection 2022.
2
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.嵌合抗原受体 (CAR) T 细胞治疗血液系统恶性肿瘤的不良反应：系统评价和 Meta 分析。
BMC Cancer. 2022 Jan 24;22(1):98. doi: 10.1186/s12885-021-09102-x.
3
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.对晚期血液系统恶性肿瘤患者进行非清髓性预处理的异基因造血细胞移植。
Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880.
4
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.嵌合抗原受体 T 细胞（CAR-T）疗法在癌症中的风险和益处：系统评价和荟萃分析。
Transfus Med Rev. 2019 Apr;33(2):98-110. doi: 10.1016/j.tmrv.2019.01.005. Epub 2019 Feb 14.
5
Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.T 细胞富含的清髓性半相合造血干细胞移植联合抗胸腺细胞球蛋白/粒细胞集落刺激因子后，血液系统恶性肿瘤患儿发生慢性移植物抗宿主病的发生率、风险因素和结局。
Biol Blood Marrow Transplant. 2020 Sep;26(9):1655-1662. doi: 10.1016/j.bbmt.2020.05.021. Epub 2020 Jun 3.
6
The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.嵌合抗原受体工程化T细胞在血液系统恶性肿瘤治疗中的前景
Cancer J. 2016 Jan-Feb;22(1):27-33. doi: 10.1097/PPO.0000000000000166.
7
Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.难治性/复发性白血病和淋巴瘤的过继性T细胞疗法：当前策略与最新进展
Ther Adv Hematol. 2015 Dec;6(6):295-307. doi: 10.1177/2040620715594736.
8
Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells.嵌合抗原受体 T 细胞治疗后的移植物抗宿主病风险：T 细胞的截然相反。
Br J Haematol. 2021 Dec;195(5):660-668. doi: 10.1111/bjh.17544. Epub 2021 May 25.
9
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis.嵌合抗原受体T细胞（CAR T）疗法治疗血液系统恶性肿瘤和实体恶性肿瘤：疗效与安全性——一项荟萃分析的系统评价
Cancers (Basel). 2019 Jan 7;11(1):47. doi: 10.3390/cancers11010047.
10
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.嵌合抗原受体 (CAR) T 疗法治疗血液系统恶性肿瘤：临床观点与意义。
J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5.
Zotero 插件